103 related articles for article (PubMed ID: 37234562)
21. Vertical transmission and humoral immune response following maternal infection with SARS-CoV-2: a prospective multicenter cohort study.
Massalha M; Yefet E; Rozenberg O; Soltsman S; Hasanein J; Smolkin T; Alter A; Perlitz Y; Nachum Z
Clin Microbiol Infect; 2022 Sep; 28(9):1258-1262. PubMed ID: 35427778
[TBL] [Abstract][Full Text] [Related]
22. Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021.
Edelstein M; Wiegler Beiruti K; Ben-Amram H; Bar-Zeev N; Sussan C; Asulin H; Strauss D; Bathish Y; Zarka S; Abu Jabal K
Clin Infect Dis; 2022 Aug; 75(1):e572-e578. PubMed ID: 35279028
[TBL] [Abstract][Full Text] [Related]
23. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
24. Levels of SARS-COV-2 anti-spike protein receptor-binding domain (S-RBD) IgG in Indonesian-vaccinated healthcare workers: experimental research.
Tambunan BA; Ugrasena IDG; Nugraha J; Fitriah M; Permatasari CA; Moses EJ; Yusoff NM; Aryati
Ann Med Surg (Lond); 2023 Apr; 85(4):802-806. PubMed ID: 37113910
[TBL] [Abstract][Full Text] [Related]
25. Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
Kanji JN; Bailey A; Fenton J; Ling SH; Rivera R; Plitt S; Sligl WI; Taylor S; Turnbull L; Tipples G; Charlton CL
Vaccine; 2021 Sep; 39(39):5563-5570. PubMed ID: 34454782
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios.
Flannery DD; Gouma S; Dhudasia MB; Mukhopadhyay S; Pfeifer MR; Woodford EC; Triebwasser JE; Gerber JS; Morris JS; Weirick ME; McAllister CM; Bolton MJ; Arevalo CP; Anderson EM; Goodwin EC; Hensley SE; Puopolo KM
JAMA Pediatr; 2021 Jun; 175(6):594-600. PubMed ID: 33512440
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M
Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009
[TBL] [Abstract][Full Text] [Related]
28. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal change in SARS-CoV-2 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study.
Leone V; Meisinger C; Temizel S; Kling E; Gerstlauer M; Frühwald MC; Burkhardt K
PLoS One; 2022; 17(8):e0272874. PubMed ID: 35951611
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
31. Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence.
Miller CN; Althoff KN; Schlueter DJ; Anton-Culver H; Chen Q; Garbett S; Ratsimbazafy F; Thomsen I; Karlson EW; Cicek M; Pinto LA; Malin BA; Ohno-Machado L; Williams C; Goldstein D; Kouame A; Ramirez A; Gebo KA; Schully SD;
mSphere; 2022 Oct; 7(5):e0025722. PubMed ID: 36173112
[TBL] [Abstract][Full Text] [Related]
32. Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
Tanaka H; Mukai J; Kushibiki K; Mizushima S; Maeda K; Fujimoto Y; Sawada R; Oda M; Okuda H; Yamaki M; Hashiguchi S; Kawai I; Kawaguchi I; Masuda N; Matsushita H
Vaccine; 2023 Jan; 41(2):365-371. PubMed ID: 36460533
[TBL] [Abstract][Full Text] [Related]
33. Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France.
Decarreaux D; Pouquet M; Souty C; Vilcu AM; Prévot-Monsacre P; Fourié T; Villarroel PMS; Priet S; Blanché H; Sebaoun JM; Deleuze JF; Turbelin C; Werner A; Kochert F; Grosgogeat B; Rabiega P; Laupie J; Abraham N; Guerrisi C; Noël H; Van der Werf S; Carrat F; Hanslik T; Charrel R; De Lamballerie X; Blanchon T; Falchi A
Viruses; 2022 May; 14(5):. PubMed ID: 35632699
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
[TBL] [Abstract][Full Text] [Related]
35. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
36. Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination.
Kurashima K; Numano T; Yoshino A; Osawa A; Takaku Y; Kagiyama N; Yanagisawa T
Vaccine; 2022 Sep; 40(39):5670-5674. PubMed ID: 36030124
[TBL] [Abstract][Full Text] [Related]
37. Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of Ireland.
Faller E; Wyse A; Barry R; Conlon K; Everard C; Finnegan P; Foran C; Herlihy E; Kerr G; Lapthorne S; McGreal-Bellone A; Morrissey E; O'Sullivan D; O'Sullivan G; Eustace JA; Spillane D; Dempsey C; Benson J; Prentice M; Gallagher J; MacSharry J; Fanning LJ; O'Riordan S; Horgan M; Sadlier C
BMJ Open; 2021 Jun; 11(6):e051415. PubMed ID: 34103324
[TBL] [Abstract][Full Text] [Related]
38. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
[TBL] [Abstract][Full Text] [Related]
39. Kinetics of Anti-SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection.
Sakhi H; Dahmane D; Attias P; Kofman T; Bouvier M; Lapidus N; Fourati S; El Karoui K;
J Am Soc Nephrol; 2021 May; 32(5):1033-1036. PubMed ID: 33637518
[TBL] [Abstract][Full Text] [Related]
40. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
